[EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT [FR] COMPOSÉS CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
[EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT [FR] COMPOSÉS CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
[EN] INHIBITORS OF PI3 KINASE AND / OR MTOR<br/>[FR] INHIBITEURS DE LA PI3 KINASE ET/OU DU MTOR
申请人:AMGEN INC
公开号:WO2010126895A1
公开(公告)日:2010-11-04
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof;
methods of treating diseases or conditions, such as cancer, using the compounds; and
pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
申请人:Wood Harold B.
公开号:US20120142706A1
公开(公告)日:2012-06-07
Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof;
methods of treating diseases or conditions, such as cancer, using the compounds; and
pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
申请人:Wood Harold B.
公开号:US08552022B2
公开(公告)日:2013-10-08
Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.